For millennia, humans have believed that aging is inevitable. Yet thirty years ago, the work of Professor Cynthia Kenyon and her colleagues showed that a single gene mutation in a worm doubled its lifespan and postponed the diseases of aging. Recent work on the naked mole rat, a mammal like us, has shown that risk of death need not increase with age. In the final episode of this season of Theory and Practice, we explore the genetic, cellular, and molecular basis of aging with Professor...

What is a thought? Some may think that question is quite abstract, but it has huge implications for science and computer design.

Psychiatry is changing and will be unrecognizable in the next 10-20 years, given our new understanding about the role of brain circuits in the generation of emotions and behavior. This week we talk to Professor Karl Deisseroth, D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University and the Howard Hughes Medical Institute.

This week we speak with Professor David Baker about the enormous scope for making new proteins and how that translates into practical uses to tackle diseases, such as Covid-19.

This week, we explore the future of cancer medicine, and there’s no better leader to turn to for that discussion than Dr. Jay Bradner. Since 2016, he’s been president of the Novartis Institutes for BioMedical Research, where he leads the discovery and development of life-changing therapies to benefit patients.

Genome editing holds the potential to be a transformative new therapy, and the pace of progress is truly breathtaking.

In this episode we explore the vastness of the dark genome and why "junk DNA" has been overlooked for so many decades.

Julia Vitarello is the mother of Mila Makovec, and the Founder and CEO of Mila’s Miracle Foundation.

Aviv Regev is a computational biologist and Executive Vice President of Genentech Research and Early Development. She was professor at the Broad Institute of MIT and Harvard and at the Department of Biology of the Massachusetts Institute of Technology, as well as investigator at the Howard Hughes Medical Institute.

Theory and Practice speaks with Dr. Amy Abernethy, previous Scientific and Medical Chief Officer of Flatiron Health, and previous Principal Deputy Commissioner of the FDA.

David Altshuler: Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.

Dr. Krishna Yeshwant is Managing Partner at GV, and a practicing physician at Brigham and Women’s Hospital in Boston.

Theory and Practice speaks with Professor Sir Rory Collins, Head of Nuffield Department of Population Health at Oxford University and BHF (British Heart Foundation) Professor of Medicine and Epidemiology. Professor Collins is also Principal Investigator and Chief Executive of the UK Biobank.